Exelixis, Inc. (NASDAQ:EXEL) traded 6.6 Million shares on last trading day with closing price of $12.08.
Advertisement
Analysts’ mean recommendation for Exelixis, Inc.’s (EXEL) stands at 1.60. Scangos George A is one of the major insider shareholder of the company’s stock, the insider owns 1,310,210 shares reported on Jan 4, 2016. They now have a Dollars 8 price target on the stock. The price range in those 12 months had a highest hit of $8.59 while lowest level in that period was $0.32. The momentum rating acts as an important barometer to show as to when a stock will attain a favourable position, which will provide a window of opportunity to benefit from equity movement in either direction. The number of shares now owned by investors are 548 mln. Schwab Gisela retains 150,247 shares in the stock after this transaction. Following the transaction, the Pres Prod Dev & Med Aff & CMO is left with a stake of 150,247 shares, now valued at $1814984. Consequent to the transaction Morrissey Michael owned a total of 71,137 shares of the stock. Analyst’s mean target price for SINA is 44.00 while analysts mean recommendation is 1.80.
Stifel issued their verdict on Exelixis, Inc. Such mean rating is based on a simplified scale of 1-5, where number one denotes a Strong Buy and number five is a Strong Sell. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. It opened the session with a $11.8 price tag, later ranging from $11.6133 to $12.22, the range at which the stock has traded at throughout the day. The firm past twelve months price to sales ratio was 11.93 and price to cash ratio remained 7.25. Company is 2.12% away from its 52 week high and is moving 132.59% ahead of its 52 week low. The firm has a 50 day moving average price of $10.28 and a 200-day moving average price of $6.73. Its previous fifty two week high was $12.22 and moved up 100.67% over the same period, now having a market cap around $2.7 billion. (NASDAQ:BRCD) declined -0.11% to $9.01. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.27) by $0.11.
Different Analysts projected the EPS Estimate for Next Quarter. The business’s quarterly revenue was up 353.7% on a year-over-year basis.
Advertisement
A current consensus EPS estimate for next quarter is at $-0.09 and 3 month ago EPS forecast was $-0.23. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc.in February 2000. The Company is engaged in developing small molecule therapies for the treatment of cancer. It focuses on advancing cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. It is approved in the US for the treatment of medullary thyroid cancer under the brand name COMETRIQ and for the treatment of kidney cancer under the brand name CABOMETYX.
